BSE Live
Feb 18, 09:04Prev. Close
884.50
Open Price
0.00
Bid Price (Qty.)
906.60 (30)
Offer Price (Qty.)
866.85 (2)
NSE Live
Feb 18, 09:04Prev. Close
884.70
Open Price
881.70
Bid Price (Qty.)
925.85 (7)
Offer Price (Qty.)
750.00 (12)
| Cash Flow of Natco Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 2,226.00 | 1,555.30 | 770.70 | 155.90 | 392.20 | |
| Net CashFlow From Operating Activities | 1,662.00 | 1,196.40 | 784.40 | 57.70 | 183.50 | |
| Net Cash Used In Investing Activities | -1,443.90 | -960.50 | -436.60 | -92.50 | -3.20 | |
| Net Cash Used From Financing Activities | -212.40 | -237.30 | -346.80 | 35.60 | -183.10 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 5.70 | -1.40 | 1.00 | 0.80 | -2.80 | |
| Cash And Cash Equivalents Begin of Year | 5.50 | 6.90 | 5.90 | 5.10 | 7.90 | |
| Cash And Cash Equivalents End Of Year | 11.20 | 5.50 | 6.90 | 5.90 | 5.10 |
16.02.2026
Natco Pharma shares rise over 11% after firm receives approval to launch Semaglutide in India
16.02.2026
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
14.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
09.09.2025
Natco Pharma Standalone June 2025 Net Sales at Rs 1,192.70 crore, down 3.57% Y-o-Y